GlassScriptPhysician profile
Sanjiv Sood
NPI 1154368298
$10,194.23
in general payments reported to CMS, 2019-2025
26 companies · $1,255 in 2025
The $1,255 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,542 · 2020: $611 · 2021: $933 · 2022: $864 · 2023: $1,234 · 2024: $755 · 2025: $1,255.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,160 · Education: $84.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,160.03 |
| Education | $84.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $4,119.75 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $2,397.10 | 2019-2025 | Xifaxan, Plenvu, Trulance |
| Janssen Biotech, INC. | $658.71 | 2022-2025 | Tremfya, Stelara, Simponi Aria |
| Abbvie INC. | $571.12 | 2019-2025 | Ubrelvy, Qulipta, Linzess |
| Redhill Biopharma INC. | $452.42 | 2020-2024 | Talicia, Movantik, Aemcolo |
| Qol Medical, LLC | $283.97 | 2019-2025 | Sucraid, Sucraid |
| Phathom Pharmaceuticals, INC. | $213.79 | 2024-2025 | Voquezna |
| Ironwood Pharmaceuticals, INC | $212.99 | 2019-2024 | Linzess |
| Braintree Laboratories, INC. | $192.37 | 2020-2023 | Sutab, Suflave |
| Madrigal Pharmaceuticals | $171.77 | 2024-2025 | Rezdiffra, Resmetirom |
| Regeneron Healthcare Solutions, INC. | $146.35 | 2022-2025 | Dupixent |
| Nestle Healthcare Nutrition INC. | $144.46 | 2021-2022 | |
| Celgene Corporation | $124.15 | 2021-2024 | Zeposia |
| Gilead Sciences, INC. | $113.85 | 2019-2023 | |
| Ardelyx, INC. | $89.79 | 2022-2025 | Ibsrela |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Digestive Care, INC. | $55.26 | 2024 | Pertzye |
| Alfasigma USA, INC. | $39.70 | 2020-2022 | |
| Cumberland Pharmaceuticals, INC. | $37.36 | 2019 | |
| Vivus LLC | $35.57 | 2020 | |
| Echosens North America, INC. | $30.00 | 2023 | Fibroscan |
| E.R. Squibb & Sons, L.L.C. | $21.31 | 2022 | |
| Pfizer INC. | $19.23 | 2025 | |
| Novo Nordisk INC | $19.11 | 2025 | Wegovy |
| Aimmune Therapeutics, INC. | $15.91 | 2025 | Zenpep |
| Genzyme Corporation | $14.28 | 2025 | |
| Exact Sciences Corporation | $13.91 | 2023 | Cologuard Collection Kit |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sanjiv Sood listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.